Literature DB >> 3733688

Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells.

R J Kaufman, L C Wasley, B C Furie, B Furie, C B Shoemaker.   

Abstract

Factor IX has been expressed to high levels within a recombinant host cell and the biologically active fraction subsequently purified to homogeneity for characterization. The coding sequence for Factor IX was inserted into a mammalian cell expression vector and transfected into dihydrofolate reductase-deficient Chinese hamster ovary cells. The integrated DNA was amplified to a high copy number by selection for increasingly higher expression levels of the marker gene, dihydrofolate reductase, contained within a co-transfected plasmid. Cloned cell lines secreting over 100 micrograms/ml Factor IX antigen and up to 1.5 microgram/ml native Factor IX antigen have been obtained. Expression of biologically active Factor IX was dependent on the presence of vitamin K in the culture media. The gamma-carboxylated Factor IX was isolated from cell culture fluid by immunoaffinity chromatography using antibodies conformation-specific for the metal-stabilized conformer of Factor IX. This conformation is dependent upon metal ions and gamma-carboxyglutamic acid. Purified recombinant Factor IX migrated as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with an electrophoretic mobility equivalent to plasma-derived Factor IX. The purified recombinant Factor IX demonstrated Factor IX coagulant activity, measured in Factor IX-deficient plasma, of 35-75 units/mg. Amino acid analysis of the alkaline hydrolysate of recombinant Factor IX demonstrated an average of 6-7 mol of gamma-carboxyglutamic acid per mol of Factor IX. NH2-terminal sequence analysis of the first 17 residues revealed equivalent amino acid sequences for both purified recombinant and plasma-derived Factor IX. The results represent the first purification and characterization of a biologically active, gamma-carboxylated vitamin K-dependent protein expressed in a recombinant DNA system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733688

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Production of recombinant proteins in serum-free media.

Authors:  D Broad; R Boraston; M Rhodes
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Authors:  Alessandra Rocca; Simona Pizzinelli; Emily Oliovecchio; Elena Santagostino; Angiola Rocino; Alfonso Iorio
Journal:  Blood Transfus       Date:  2010-04-30       Impact factor: 3.443

3.  r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.

Authors:  Kevin W Hallgren; Wen Qian; Anna V Yakubenko; Kurt W Runge; Kathleen L Berkner
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

4.  siRNA silencing of calumenin enhances functional factor IX production.

Authors:  Nadeem Wajih; Susan M Hutson; Reidar Wallin
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

5.  Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection.

Authors:  Nadeem Wajih; John Owen; Reidar Wallin
Journal:  Thromb Res       Date:  2008-01-03       Impact factor: 3.944

Review 6.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

7.  Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Authors:  A Preininger; U Schlokat; G Mohr; M Himmelspach; V Stichler; A Kyd-Rebenburg; B Plaimauer; P L Turecek; H P Schwarz; W Wernhart; B E Fischer; F Dorner
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

Review 8.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 9.  Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

Authors:  C Vermeer
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

10.  Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin.

Authors:  R Drews; R K Paleyanda; T K Lee; R R Chang; A Rehemtulla; R J Kaufman; W N Drohan; H Luboń
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.